Artal Group S.A. Spero Therapeutics, Inc. Transaction History

Artal Group S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$11.65 - $22.07 $1.17 Million - $2.21 Million	-100,000 Reduced 16.67%	500,000 $9.7 Million
Q3 2020 Nov 13, 2020	BUY	$8.96 - $14.12 $492,441 - $776,035	54,960 Added 10.08%	600,000 $6.7 Million
Q2 2020 Aug 14, 2020	SELL	$7.27 - $14.18 $225,079 - $439,012	-30,960 Reduced 5.38%	545,040 $7.37 Million
Q1 2020 May 14, 2020	BUY	$5.27 - $10.41 $400,519 - $791,160	76,000 Added 15.2%	576,000 $4.65 Million
Q4 2019 Feb 13, 2020	SELL	$9.46 - $12.16 $378,400 - $486,400	-40,000 Reduced 7.41%	500,000 $4.81 Million
Q2 2019 Aug 09, 2019	SELL	$10.25 - $14.36 $615,000 - $861,600	-60,000 Reduced 10.0%	540,000 $6.22 Million
Q3 2018 Nov 09, 2018	BUY	$9.69 - $17.79 $2.42 Million - $4.45 Million	250,000 Added 71.43%	600,000 $6.31 Million
Q4 2017 Feb 09, 2018	BUY	$10.43 - $14.75 $3.65 Million - $5.16 Million	350,000	350,000 $4.11 Million

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $33.3M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.